FK506 FK506 2005 17 4 1 1,2) 1 1943 18 12 1944 9 11 1946 4 2 11 J. W. 1948 26 2 1949 11 19511954 E-mail: michio.yamashita@astellas.com 2013 3 141
1956 4 1 10 1 1961 10 NRDC C CC CC CC CC CCNa 1962 7-7ACA 1963 7ACA 1968 10 1971 48 23 1976 1978 FK156 FK565 FK565 FK156 1970 A CsA 1972 J. T 1986 CsA 1982 FK506 FK506 1983 4 1 1984 3 FK506 1 3 6) 11 142 91
1993 4 6 FK506 1999 11 2 Candida FR901379 1989 FR179642 FK463 2001 6 2002 1012 6 7) 40 1990 HDAC FK228ras NIH- 3T3 I II 2004 4 Gloucester 2009 1FDA Food and Drug Administration, 32009 11 FDA T cutaneous T-cell lymphoma, CTCLIstodax Romidepsin Celgene 2011 6 T peripheral T-cell lymphoma, PTCL FDA 1960 T T 3 6) T T IL-2 IL-2 IL-2 1) 3 H- 3 1983 4 1 1984 3 8000 12,000 No.9993 Streptomyces tsukubaensis No.9993 1500 l HP20 13.6 g 4 2 1) mixed lymphocyte reaction MLR 2 2013 3 143
127 129 C C44H69NO12 H2O 5) FK506 X FK506 L- 6,8) FR900506 FR, Fujisawa Research No. FK506 FK, Fujisawa Kaihatsu No. Tsukuba t macrolide acrol immunosuppressant ims tacrolimus FK506 No.9993 FK506 FR900525 FR901154 FR901155 FR900520 FR900523 9) 3 T in vitro 2) T IL-2 IL-3 INF- IL-2 CsA 50 100 in vivo 3) CsA 3 6) II 1 SLE 41 FK506 1987 5 13 1 FK506 2) in vitro 3) in vivo 144 91
FK506 FK506 FK506 ELISA FK506 FK506 FK506 50 pg/ml 1993 Abbott IMX 2 3 g/ml 0.5 24 BA 20 CsA 14 C-FK506 14 C Amersham GE 1990 12 FK506 in vivo F344 WKA 6.4 5 FK506 0.1 mg/kg 8.4 0.32 mg/kg 14.0 3.2 mg/kg 42.9 5 6 FK506 0.32 mg/kg 4 FK506 CsA 10 30 14 C-FK506 Tmax 1 BA, bioavailability 14 14 C-FK506 24 FK506 8 Tmax 4.2 5 2013 3 145
1984 100 FK506 10 T 6 FKFKBP FK506 FKBP FK506 FKBP FK506 FK506-FKBP 6 T FK506 1984 3 FK506 1987 5 1967 12 1958 1968 8 2 30 1999 1988 12 1989 3 146 91
2 1992 1 1997 7 16 10 16-1 1986 8 11 FK506 E FK506 FK506 FK506 1987 6 3FK506 FK506 1987 FK506 FDAIND Investigational New Drug1986 12 1989 3 FK506 27 FK506 FK506 FK506 FK506 FK506-2 1989 10 4 FK506 1991 8 1 FK506 1992 8 14 2013 3 147
1993 5 12 19 10 6 1994 8 28 9 26 15 1500 500 2000 FK506 60 FK506 FK506 1990 12 4 8 1989 10 18 1 FK506 11 2001 1 FK506 1991 4 FK506 1989 11 FK506 FK506 FK506 1990 6 FK506 1991 1036 24 FK506 1991 12 4) FK506 1993 6 7 USA 12 1994 2 USA 245 FK506 10 1986 4)Orphan Drug 5 10 148 91
10 FK506 1 FK506 10) FK506 1 FK506 HPLC FK506 11) FDA EMEA European Medicines Agency GMP 5) 1989 FK506 FK506 7ACA 5) GMP: Good Manufacturing Practice FDA 1938 FK506 FK506 FK506 FIL 1992 8 21 GMP 1992 1 1981 10 2013 3 149
1992 7 PV 6) FDA 7) FDA 1993 12 100 1 100 FK506 FK506 FDA EMEA 1991 12 11993 4 6) Process Validation PV GMP 7) GMP 5 6 1992 10 10 500 1994 9 1996 4 2000 9 2009 7 1993 6 1996 1994 4 6 1994 6 USA 150 91
10 10 2003 67 2012 100 1997 6 0.11999 6 11 Topical Immunomodurators TIM 40 2000 7 2003 70.03 12 FHI 1999 9 0.1 0.032 FDA 2000 12 FDA 0.10.03 2 15 2001 2 2001 9 5 2004 34 70 1999 9 2000 2 9 2001 1 6 1 2 1 1 FK506 2006 5 2008 7 16 10 28 Graceptor Advagraf XL 19 2000 18 2011 4 7 28 201240 2002 1 2005 12 13 2008 1 25 4 2012 FHI GI 1999 11 2000 12 FDA 2001 9 2002 1 4 2002GI 2013 3 151
2000 4 38 6000 1 2700 m 2 2001 2 100 35 2002 FK506 2004 FK506 FK506 GMP -1 30-2 2 1 FR179642 FDA FK506-1 30 1 FDA EMEA 80 2000 4 8110 m 2 2001 5 2 1 4 6 2004 2007 18 152 91
BSE 2012 6 2012 120 2010 2011 4 10 6 6 2012 6 14 15 10 60 18 50 2012 3 29 1997 102 2012 3 30 268 1999 3 2011 4 102 2011 80 76 95 32 123 112 91 2011 88 82 65 79 79 FK506 1 9 FK506 1 2 in vitro 3 1 1 4 CsA 1 1 1995 7 4 1996 8 1 1997 9 3 1997 9 9 2000 12 1 2001 13 3 2003 15 11 2004 16 5 FK506 FK506 2013 3 153
2010 1 1) 100 (1994). 2) 10011 (2005). 3), 168, 163 (1994). 4), 70, 1 (1996). 5) Kino, T. et al.: J. Antibiotics, 40, 1249 (1987). 6), 117, 542 (1997). 7), 83, 123 (2005). 8) Tanaka, H. et al.: J. Am. Chem. Soc., 109, 5031 (1987). 9) Hatanaka, H. et al.: J. Antibiotics, 41, 1586 (1988). 10), 76, 389 (1998). 11) Akashi, T. et al.: J. Pharm. Biomed. Anal., 14, 330 (1996). 291 3 91 4 154 91